IVIG - BMC HealthNet Plan

17. Buchanan GR, de Alarcon PA, Feig SA, et al. Acute idiopathic thrombocytopenic
purpura – management in childhood. Blood. 1997;89:1464-1465.
18. Newburger JW, Takahashi M, Gerber MA, et al; Committee on Rheumatic Fever,
Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the
Young; American Heart Association; American Academy of Pediatrics. Diagnosis,
treatment, and long-term management of Kawasaki disease: a statement for health
professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki
Disease, Council on Cardiovascular Disease in the Young, American Heart
Association. Circulation. 2004;110:2747-2771.
19. Hughes RA, Donofrio P, Bril V, et al; ICE Study Group. Intravenous immune
globulin (10% caprylate-chromatography purified) for the treatment of chronic
inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised
placebo-controlled trial. Lancet Neurol. 2008;7:136-144.
20. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune
globulin for neurologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S57-107.
21. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
JAMA. 2004;291:2367-2375.
22. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol
Neurosurg Psychiatry. 2003;74 Suppl 2:ii9-ii14.
23. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in
human disease: A review of evidence by members of the Primary Immunodeficiency
Committee of the American Academy of Allergy, Asthma and Immunology. J
Allergy Clin Immunol. 2006;117(4 Suppl):S525-553.
24. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of
intravenously administered immunoglobulin preparations. JAMA. 1995;273:1865-
1870.
25. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am
Pharm Assoc. 2002;42:449-459.
26. Bonilla FA, Bernstein IL, Khan DA, et al; American Academy of Allergy, Asthma
and Immunology; American College of Allergy, Asthma and Immunology; Joint
Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis
and management of primary immunodeficiency. Ann Allergy Asthma Immunol.
2005;94(5 Suppl 1):S1-63.
27. British Columbia Blood Coordinating Office. IVIG utilization management
handbook. 1st Ed. British Columbia, Canada: Provincial Blood Coordinating Office;
April 2002. Available at:
http://www.pbco.ca/images/Resources/Publications/ivighandbook-combined.pdf.
Accessed January 11, 2011.
28. Gammaplex [package insert]. Temecula, CA: FFF Enterprises, Inc. (manufactured by
Bio Products Laboratory, Hertfordshire, UK); June 2010.
29. Provan D, Stasi R, Newland AC, et al. International consensus report on the
investigation and management of primary immune thrombocytopenia. Blood.
2010;115:168-186.
This guideline provides information on BMC HealthNet Plan claims adjudication processing guidelines. The use of this
guideline is not a guarantee of payment and will not determine how a specific claim(s) will be paid. Reimbursement is
based on member benefits and eligibility, medical necessity review, where applicable, coordination of benefits, adherence
to Plan policies, clinical coding criteria, and the BMC HealthNet Plan agreement with the rendering or dispensing provider.
Reimbursement policies may be amended at BMC HealthNet Plan’s discretion. BMC HealthNet Plan will always use the
most recent CPT and HCPCS coding guidelines.
BMC HealthNet Plan – IVIG
34 of 45